OliX Pharmaceuticals names Dmitry Samarsky as its SVP of Technology and Global Business Development
"Dr. Samarsky brings to OliX exceptional expertise and experience in discovery, development, manufacturing, promotion and collaborations in the area of oligonucleotide technologies and therapeutics, including RNAi" said Dr. Dong-ki Lee, Founder and CEO of OliX. "Dmitry will steer advancement of our oligonucleotide technologies and help strengthen and expand OliX’s relationship with biopharma worldwide".
Dr. Samarsky has authored dozens of articles, reviews, book chapters, patents and patent applications in the field of RNA. Over the past 15 years, he has presented at, served as an advisor for and helped organize more than 100 academic and industry conferences related to RNA science and technology. Dr. Samarsky earned his PhD in biochemistry and molecular biology from University of Massachusetts, Amherst, followed by postdoctoral position as H. Arthur Smith Fellow for Cancer Research in laboratory of Dr. Michael Green at University of Massachusetts Medical School.
“OliX has demonstrated creativity in developing its proprietary oligonucleotide technology platform, deep understanding of underlying in vivo delivery challenges, and practicality in selecting therapeutic targets and indications,”
OliX Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics against a variety of disorders based on RNAi (RNA interference)
Jung Hwan Lee
Page Updated Last on: Jan 08, 2016